IDSA Releases Guidance On Treatment Of Antimicrobial-Resistant Infections
Developed by a panel of six infectious diseases specialists with clinical and research expertise in the treatment of AMR bacterial infections, this first-in-a-series guidance addresses three groups of AMR Gram-negative bacteria that pose particular therapeutic challenges and have been designated as urgent or serious threats by CDC:
- Extended-spectrum β-lactamase producing Enterobacterales (ESBL-E)
- Carbapenem-resistant Enterobacterales (CRE)
- Difficult-to-treat resistance (DTR)-Pseudomonas aeruginosa
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.